Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?

Gastric cancer is the third leading cause of cancer-related death globally with approximately 723 000 deaths every year. Most patients present with advanced unresectable or metastatic disease, only amenable to palliative systemic treatment and a median survival uncommonly exceeding 12 months. Over t...

Descripción completa

Detalles Bibliográficos
Autores principales: Salati, Massimiliano, Di Emidio, Katia, Tarantino, Vittoria, Cascinu, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703389/
https://www.ncbi.nlm.nih.gov/pubmed/29209523
http://dx.doi.org/10.1136/esmoopen-2017-000206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703389/
https://www.ncbi.nlm.nih.gov/pubmed/29209523
http://dx.doi.org/10.1136/esmoopen-2017-000206

Ejemplares similares